Based on the guidance from the documentation published by the European Medicines Agency (EMA, 2020) and U.S FDA issued EUA, remdesivir is contraindicated in the following clinical situations unless the potential benefit of the use of remdesivir outweighs the potential risks:

- Patients with alanine aminotransferase (ALT) levels >5-times upper limit of normal or severe hepatic dysfunction

- Adult and pediatric patients (>28 days old) with severe renal impairment described as eGFR < 30 ml/min

- Neonates (at least seven days to ≤ 28 days old) with serum creatinine ≥1 mg/dL